Results 161 to 170 of about 12,961,080 (334)

Exploring biomarkers of neurodegeneration in epilepsy: Critical insights

Epileptic Disorders, EarlyView.
Abstract The advent of biofluid biomarkers for neurodegenerative disorders has precipitated a surge in recent evidence regarding their role in epilepsy. In this literature review, we examine the diagnostic, prognostic, and therapeutic potential of several biomarkers, including amyloid‐beta (Aβ) protein, total (t‐tau), phosphorylated tau (p‐tau) protein,
Rida Farhan, Syeda Amrah Hashmi, Jaideep Kapur, Anelyssa D'Abreu, Vineet Punia, Carol Manning, Vanessa L. Smith, Ifrah Zawar   +7 more
wiley   +1 more source

The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life.

, 1989
Clive R. Pullinger, Julia D. North, Ba‐Bie Teng, Vincent A. Rifici, A E Ronhild de Brito, Jenny Scott   +5 more
openalex   +1 more source

Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics

Proteins: Structure, Function, and Bioinformatics, EarlyView., 2023
Abstract Before the controversial approval of humanized monoclonal antibody lecanemab, which binds to the soluble amyloid‐β protofibrils, all the treatments available earlier, for Alzheimer's disease (AD) were symptomatic. The researchers are still struggling to find a breakthrough in AD therapeutic medicine, which is partially attributable to lack in ...
Sharif Arar, Md Anzarul Haque, Rakez Kayed   +2 more
wiley   +1 more source

Human liver apolipoprotein B-100 cDNA: complete nucleic acid and derived amino acid sequence.

, 1986
S W Law, Sabrina Grant, Kayoko Higuchi, Ashok Hospattankar, Karl J. Lackner, N Lee, H. Bryan Brewer   +6 more
openalex   +1 more source

Human aortic fibrolipid lesions. Immunochemical localization of apolipoprotein B and apolipoprotein A. [PDF]

, 1988
Thomas Bocan, Sarah Annes Brown, John R. Guyton   +2 more
openalex   +1 more source

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

CPT: Pharmacometrics &Systems Pharmacology, Volume 11, Issue 12, Page 1578-1591, December 2022., 2022
Abstract Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) and PK/pharmacodynamic (PD) analyses for amyloid plaques, as measured using positron emission tomography (PET), and ...
Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, Ziad Hussein   +8 more
wiley   +1 more source

Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE.

Journal of Lipid Research, 1994
The present work describes a procedure for determining apolipoproteins (apo) B-100 and B-48 in subfractions of triglyceride-rich lipoproteins by analytical sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie staining.
F Karpe, A Hamsten
doaj  

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 62-73, January 2023., 2023
Abstract Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the design of clinical trials in AD.
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino   +15 more
wiley   +1 more source

Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans

Journal of Lipid Research, 2003
Numerous factors are known to affect the plasma metabolism of HDL, including lipoprotein receptors, lipid transfer protein, lipolytic enzymes and HDL apolipoproteins.
Jeffrey S. Cohn, Rami Batal, Michel Tremblay, Hélène Jacques, Lyne Veilleux, Claudia Rodriguez, Orval Mamer, Jean Davignon   +7 more
doaj  

Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses.

, 1985
Bunyen Teng, Allan D. Sniderman, Ronald M. Krauss, Peter O. Kwiterovich, R W Milne, Yves L. Marcel   +5 more
openalex   +1 more source